. . "Take after a meal (always the same meal), product bioavailability is reduced when taken on an empty stomach."@en . . . "81403-80-7"@en . "10 hours"@en . "Alfuzosinum"@en . . . . . . . " "@en . . . "Absorption is 50% lower under fasting conditions"@en . "Side effects are dizziness (due to postural hypotension), upper respiratory tract infection, headache, and fatigue."@en . "Alfuzosin"@en . "(\u00B1)-N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furamide "@en . "82%-90%"@en . "# McKeage K, Plosker GL: Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11893233 # Wilde MI, Fitton A, McTavish D: Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs. 1993 Mar;45(3):410-29. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7682910 # Andersson KE, Lepor H, Wyllie MG: Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate. 1997 Feb 15;30(3):202-15. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/9122046 # Elhilali MM: Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Expert Opin Pharmacother. 2006 Apr;7(5):583-96. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16553574 # Roehrborn CG: Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. Urology. 2001 Dec;58(6 Suppl 1):55-63; discussion 63-4. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11750253"@en . . . . . . . . . . "Humans and other mammals"@en . . "Alfuzosin (INN, provided as the hydrochloride salt) is an alpha-adrenergic blocker used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate. [Wikipedia]"@en . . . . "For the reduction of urinary obstruction and relief of associated manifestations (eg. sensation of incomplete bladder emptying or straining, urgency, interrupted or weak stream) in patients with symptomatic beningn prostatic hyperplasia."@en . . "approved"@en . . . . . "Alfuzosin"@en . . "Mathias Scheer, \"Alfuzosin tablets and synthesis.\" U.S. Patent US20060062845, issued March 23, 2006."@en . . . . "N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide"@en . . " "@en . . . . . . "Alfuzosin is a non-subtype specific alpha(1)-adrenergic blocking agent that exhibits selectivity for alpha(1)-adrenergic receptors in the lower urinary tract. Inhibition of these adrenoreceptors leads to the relaxation of smooth muscle in the bladder neck and prostate, resulting in the improvement in urine flow and a reduction in symptoms in benign prostate hyperplasia. Alfuzosin also inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation."@en . "Alfuzosine"@en . . "Following oral administration of 14C-labeled alfuzosin solution, the recovery of radioactivity after 7 days (expressed as a percentage of the administered dose) was 69% in feces and 24% in urine."@en . . . "Alfuzosina"@en . . . . . . . . . . . . "investigational"@en . . . . . . . . . . . . "* 3.2 L/kg [healthy male middle-aged volunteers]"@en .